Geneva, Switzerland and Boston, MA – November 7, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in the investor conferences listed below:

• The Jefferies London Healthcare Conference taking place in London November 14-15, 2018. ObsEva will be presenting on Wednesday November 14 at 10 a.m. Greenwich Mean Time (GMT). 

• The Credit Suisse Healthcare Conference taking place November 13-15 in Scottsdale, AZ.  ObsEva will be presenting on Thursday November 15 at 8 a.m.  Mountain Standard Time (MST). 

Presentation webcasts will be available in the “Investors” section of ObsEva’s website www.ObsEva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

Media Contact Switzerland and Europe:Christophe LampsDynamics Groupcla@dynamicsgroup.ch +41 22 308 6220 Office+41 79 476 26 87 Mobile

Media Contact U.S.:Marion JanicRooneyPartners LLCmjanic@rooneyco.com+1 212 223 4017 Office+1 646 537 5649 Mobile

CEO Office Contact:Shauna DillonShauna.dillon@obseva.ch+41 22 552 1550

Investor Contact:Mario CorsoSenior Director, Investor Relationsmario.corso@obseva.com+1 857 972 9347 Office+1 781 366 5726 Mobile

Attachment

• Press Release in Pdf